全文获取类型
收费全文 | 16279篇 |
免费 | 1065篇 |
国内免费 | 129篇 |
专业分类
耳鼻咽喉 | 141篇 |
儿科学 | 486篇 |
妇产科学 | 467篇 |
基础医学 | 2503篇 |
口腔科学 | 284篇 |
临床医学 | 1335篇 |
内科学 | 3817篇 |
皮肤病学 | 386篇 |
神经病学 | 2254篇 |
特种医学 | 506篇 |
外科学 | 1466篇 |
综合类 | 39篇 |
一般理论 | 1篇 |
预防医学 | 921篇 |
眼科学 | 177篇 |
药学 | 1127篇 |
中国医学 | 34篇 |
肿瘤学 | 1529篇 |
出版年
2024年 | 29篇 |
2023年 | 204篇 |
2022年 | 439篇 |
2021年 | 736篇 |
2020年 | 401篇 |
2019年 | 496篇 |
2018年 | 649篇 |
2017年 | 473篇 |
2016年 | 543篇 |
2015年 | 605篇 |
2014年 | 742篇 |
2013年 | 986篇 |
2012年 | 1398篇 |
2011年 | 1396篇 |
2010年 | 799篇 |
2009年 | 722篇 |
2008年 | 1172篇 |
2007年 | 1063篇 |
2006年 | 969篇 |
2005年 | 858篇 |
2004年 | 781篇 |
2003年 | 694篇 |
2002年 | 528篇 |
2001年 | 57篇 |
2000年 | 43篇 |
1999年 | 62篇 |
1998年 | 120篇 |
1997年 | 77篇 |
1996年 | 58篇 |
1995年 | 49篇 |
1994年 | 49篇 |
1993年 | 28篇 |
1992年 | 19篇 |
1991年 | 20篇 |
1990年 | 23篇 |
1989年 | 18篇 |
1988年 | 14篇 |
1987年 | 17篇 |
1986年 | 17篇 |
1985年 | 16篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 17篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1977年 | 8篇 |
1976年 | 9篇 |
1967年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
151.
152.
Alessandra Vergori Antonio Boschini Stefania Notari Patrizia Lorenzini Concetta Castilletti Francesca Colavita Giulia Matusali Eleonora Tartaglia Roberta Gagliardini Andrea Boschi Eleonora Cimini Markus Maeurer Pierluca Piselli Leila Angeli Andrea Antinori Chiara Agrati Enrico Girardi 《Viruses》2022,14(7)
The main aim of this study was to describe the clinical and immunological outcomes, as well as the inflammatory profile, of patients with advanced HIV in an assisted-living facility in which an outbreak of SARS-CoV-2 occurred. SARS-CoV-2 humoral and specific T-cell response were analyzed in patients with HIV infection and COVID-19; as a secondary objective of the analysis, levels of the inflammatory markers (IL-1β, IL-6, IL-8, and TNFα) were tested in the HIV/COVID-19 group, in HIV-positive patients without COVID-19, and in HIV-negative patients with mild/moderate COVID-19. Antibody kinetics and ability to neutralize SARS-CoV-2 were evaluated by ELISA assay, as well as the inflammatory cytokines; SARS-CoV-2 specific T-cell response was quantified by ELISpot assay. Mann–Whitney or Kruskal–Wallis tests were used for comparisons. Thirty patients were included with the following demographics: age, 57 years old (IQR, 53–62); 76% male; median HIV duration of infection, 18 years (15–29); nadir of CD4, 57/mmc (23–100) current CD4 count, 348/mmc (186–565). Furthermore, 83% had at least one comorbidity. The severity of COVID-19 was mild/moderate, and the overall mortality rate was 10% (3/30). Additionally, 90% of patients showed positive antibody titers and neutralizing activity, with a 100% positive SARS-CoV-2 specific T-cell response over time, suggesting the ability to induce an effective specific immunity. Significantly higher levels of IL-6, IL-8, and TNF-α in COVID-19 without HIV vs. HIV/COVID-19 patients (p < 0.05) were observed. HIV infection did not seem to negatively impact COVID-19-related inflammatory state and immunity. Further data are mandatory to evaluate the persistence of these immunity and its ability to expand after exposure and/or vaccination. 相似文献
153.
Simone Perna Clara Gasparri Cinzia Ferraris Gaetan Claude Barrile Alessandro Cavioni Francesca Mansueto Zaira Patelli Gabriella Peroni Alice Tartara Marco Zese Mariangela Rondanelli 《Nutrients》2022,14(12)
Background: SARC-F is a simple sarcopenia screening tool. This study aimed to examine the validity of the Italian version of SARC-F. Methods: A total of 97 elderly individuals (37/60 males/females, 65 years and older) who met the study’s selection criteria were included. SARC-F was translated into the Italian language in a culturally responsive manner. The total score was calculated by adding the scores on the five items. The participants were divided into two groups according to the total score (SARC-F < 4 vs. SARC-F ≥ 4), and their associations with various factors (handgrip test, chair stand test, and Skeletal Muscle Index assessed by DXA) have been examined by gender. In addition, the tool’s validity was analyzed by comparing it with different international working group diagnostic criteria for sarcopenia. Results: The total prevalence of sarcopenia according to the SARC-F was 14.2% and, specifically, 12.8% among men and 14.3% in women. The sensitivity of the SARC-F was (male (M): 11–50% and female (F): 22–36%) medium-low compared with the European, international, and Asian criteria of sarcopenia; however, SARC-F showed a high specificity (M: 77.3–100% and F: 79.5–100%) and a moderate Cronbach’s alpha coefficient of (0.669 (CI95%: 0.358–0.830). The participants in the SARC-F ≥ 4 group had poorer handgrip for EWGSOP2 (p < 0.001) and chair stand (p < 0.001) than the participants in the SARC-F < 4 group. Conclusions: The Italian language version of SARC-F showed high specificity, moderate reliability, and good associations with other predictive tests. The Italian version of SARC-F appears to be a useful screening tool for the diagnosis of sarcopenia in Italian elderly populations. 相似文献
154.
Emmanuel de Billy Marsha Pellegrino Domenico Orlando Giulia Pericoli Roberta Ferretti Pietro Businaro Maria Antonietta Ajmone-Cat Sabrina Rossi Lucia Lisa Petrilli Nicola Maestro Francesca Diomedi-Camassei Marco Pezzullo Cristiano De Stefanis Paola Bencivenga Alessia Palma Rossella Rota Francesca Del Bufalo Luca Massimi Gerrit Weber Chris Jones Andrea Carai Simona Caruso Biagio De Angelis Ignazio Caruana Concetta Quintarelli Angela Mastronuzzi Franco Locatelli Maria Vinci 《Neuro-oncology》2022,24(7):1150
BackgroundDiffuse midline gliomas (DMG) H3K27M-mutant, including diffuse intrinsic pontine glioma (DIPG), are pediatric brain tumors associated with grim prognosis. Although GD2-CAR T-cells demonstrated significant anti-tumor activity against DMG H3K27M-mutant in vivo, a multimodal approach may be needed to more effectively treat patients. We investigated GD2 expression in DMG/DIPG and other pediatric high-grade gliomas (pHGG) and sought to identify chemical compounds that would enhance GD2-CAR T-cell anti-tumor efficacy.MethodsImmunohistochemistry in tumor tissue samples and immunofluorescence in primary patient-derived cell lines were performed to study GD2 expression. We developed a high-throughput cell-based assay to screen 42 kinase inhibitors in combination with GD2-CAR T-cells. Cell viability, western blots, flow-cytometry, real time PCR experiments, DIPG 3D culture models, and orthotopic xenograft model were applied to investigate the effect of selected compounds on DIPG cell death and CAR T-cell function.ResultsGD2 was heterogeneously, but widely, expressed in the tissue tested, while its expression was homogeneous and restricted to DMG/DIPG H3K27M-mutant cell lines. We identified dual IGF1R/IR antagonists, BMS-754807 and linsitinib, able to inhibit tumor cell viability at concentrations that do not affect CAR T-cells. Linsitinib, but not BMS-754807, decreases activation/exhaustion of GD2-CAR T-cells and increases their central memory profile. The enhanced anti-tumor activity of linsitinib/GD2-CAR T-cell combination was confirmed in DIPG models in vitro, ex vivo, and in vivo.ConclusionOur study supports the development of IGF1R/IR inhibitors to be used in combination with GD2-CAR T-cells for treating patients affected by DMG/DIPG and, potentially, by pHGG. 相似文献
155.
Lorenzo Fornaro Gianna Musettini Paola Orlandi Irene Pecora Caterina Vivaldi Marta Banchi Francesca Salani Elisabetta Fini Valentina Massa Silvia Catanese Federico Cucchiara Monica Lencioni Gianluca Masi Enrico Vasile Guido Bocci 《American journal of cancer research》2022,12(7):3347
Ramucirumab plus paclitaxel is considered the standard of care in the second-line treatment of gastric carcinoma (GC). The aim of this study was to evaluate plasma vascular endothelial growth factor-A (VEGF-A), VEGF-D, and circulating soluble VEGF receptor-2 (sVEGFR-2) as possible markers of resistance or response to ramucirumab administered with paclitaxel in pretreated metastatic GC patients. Plasma samples were collected at different time points (on days 1 and 15 of the first 3 cycles, at best radiologic response and at disease progression). VEGF-A, VEGF-D and sVEGFR-2 were analysed by ELISA. Correlations of biomarker baseline levels or dynamic changes with outcome measures were assessed. Progression-free survival (PFS) was the primary endpoint of the study. Forty-one patients were enrolled. VEGF-A and VEGF-D, but not sVEGFR-2, values significantly increased during treatment compared to baseline (P < 0.001). A positive correlation between VEGF-A and sVEGFR-2 at cycle 2 was found (P=0.045). At univariate analysis, higher baseline levels of VEGF-A were associated with worse OS (P=0.015). Early increase of sVEGFR-2 levels after the first treatment cycle was the only factor associated with longer PFS (6.6 vs. 3.6 months, P=0.049) and OS (18.6 vs. 5.2 months, P=0.008). Significance of sVEGFR-2 early increase was retained at multivariate analysis for OS (HR 0.32; 95% CI 0.12-0.91; P=0.032). The reported results confirmed the prognostic role of baseline VEGF-A and, with the limitations of the limited sample size and the lack of a control arm, suggested that the early increase of sVEGFR-2 after 1 cycle of treatment could be a potential predictive biomarker of benefit from second-line ramucirumab plus paclitaxel in GC. 相似文献
156.
Stephanie T.Kuwahara Shuwan Liu Andrew Chareunsouk Maxwell Serowoky Francesca V.Mariani 《骨研究(英文版)》2022,(1):20-30
Uncovering the molecular pathways that drive skeletal repair has been an ongoing challenge. Initial efforts have relied on in vitro assays to identify the key signaling pathways that drive cartilage and bone differentiation. While these assays can provide some clues, assessing specific pathways in animal models is critical. Furthermore, definitive proof that a pathway is required for skeletal repair is best provided using genetic tests. Stimulating the Hh(Hedgehog) pathway can promote cartilage ... 相似文献
157.
Francesca Di Giallonardo Ilaria Puglia Valentina Curini Cesare Camm Iolanda Mangone Paolo Calistri Joanna C. A. Cobbin Edward C. Holmes Alessio Lorusso 《Viruses》2021,13(5)
Italy’s second wave of SARS-CoV-2 has hit hard, with more than three million cases and over 100,000 deaths, representing an almost ten-fold increase in the numbers reported by August 2020. Herein, we present an analysis of 6515 SARS-CoV-2 sequences sampled in Italy between 29 January 2020 and 1 March 2021 and show how different lineages emerged multiple times independently despite lockdown restrictions. Virus lineage B.1.177 became the dominant variant in November 2020, when cases peaked at 40,000 a day, but since January 2021 this is being replaced by the B.1.1.7 ‘variant of concern’. In addition, we report a sudden increase in another documented variant of concern—lineage P.1—from December 2020 onwards, most likely caused by a single introduction into Italy. We again highlight how international importations drive the emergence of new lineages and that genome sequencing should remain a top priority for ongoing surveillance in Italy. 相似文献
158.
159.
Maria Antonia De Francesco Claudio Poiesi Franco Gargiulo Carlo Bonfanti Patrizia Pollara Simona Fiorentini Francesca Caccuri Valentina Carta Lucia Mangeri Simone Pellizzeri Damiano Rizzoni Paolo Malerba Massimo Salvetti Maria Lorenza Muiesan Federico Alberici Francesco Scolari Andrea Pilotto Alessandro Padovani Arnaldo Caruso 《The Journal of infection》2021,82(4):e4-e7
160.